Our Pricing

Wegovy vs Saxenda: Compare UK Weight Loss Treatments

Published on: June 03, 2026

Choosing between a wegovy vs saxenda uk comparison requires understanding how these two licensed weight loss injections differ in mechanism, efficacy, and suitability. Both are GLP-1 receptor agonists approved by the MHRA for weight management, but they use different active ingredients and dosing schedules that may make one more appropriate for your individual circumstances than the other.

How Wegovy and Saxenda Work: Understanding the Mechanisms

Wegovy contains semaglutide, a once-weekly GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1 [1]. By activating GLP-1 receptors in the brain, pancreas, and gastrointestinal tract, semaglutide slows gastric emptying, reduces appetite, and improves glycaemic control. This multi-pathway approach helps patients feel fuller for longer and reduces food cravings between meals.

Saxenda contains liraglutide, an earlier-generation GLP-1 receptor agonist that requires daily subcutaneous injection [2]. While liraglutide works through the same GLP-1 receptor pathway as semaglutide, its shorter half-life necessitates daily dosing to maintain therapeutic levels. Both medications are licensed in the UK for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity, subject to prescriber approval.

The key pharmacological difference lies in their molecular structure and duration of action. Semaglutide's extended half-life of approximately 7 days allows for weekly administration, whereas liraglutide's 13-hour half-life requires daily injections to sustain clinical effects [1][2]. This distinction impacts not only convenience but also steady-state drug levels and patient adherence over time.

Wegovy vs Saxenda Weight Loss Results: Clinical Trial Data

In the landmark STEP 1 trial, participants using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Notably, 86.4% of semaglutide-treated patients lost at least 5% of their baseline weight, and 69.1% achieved at least 10% weight reduction — outcomes that represent substantial clinical improvement in weight-related health markers.

The SCALE Obesity and Prediabetes trial evaluated Saxenda over 56 weeks, with participants achieving an average weight loss of 8.0% compared to 2.6% with placebo [2]. While 63.2% of liraglutide-treated patients lost at least 5% of their body weight, the magnitude of weight reduction was notably lower than that observed with semaglutide in head-to-head comparisons.

A 2021 network meta-analysis comparing GLP-1 receptor agonists for weight management found that semaglutide demonstrated superior efficacy to liraglutide across multiple endpoints, with an estimated additional 5-6% body weight reduction at comparable timepoints [3]. These findings suggest that while both treatments produce clinically meaningful weight loss, Wegovy may offer greater efficacy for patients seeking maximum weight reduction, subject to individual response and prescriber assessment.

Real-World Weight Loss Expectations

Clinical trial results represent controlled conditions with structured dietary and exercise programmes. In real-world UK practice, individual results vary based on baseline metabolic health, adherence to lifestyle modifications, and genetic factors affecting GLP-1 receptor sensitivity. Your prescriber will set realistic expectations during your consultation and monitor your progress with regular follow-up assessments to optimise outcomes.

Dosing Schedules and Administration: Wegovy vs Saxenda

Wegovy follows a gradual dose escalation protocol starting at 0.25 mg once weekly, increasing every four weeks through 0.5 mg, 1 mg, and 1.7 mg, until reaching the maintenance dose of 2.4 mg weekly [1]. This titration schedule minimises gastrointestinal side effects while allowing your body to adapt to increasing semaglutide levels. Each pre-filled pen delivers a single dose, and injections are administered subcutaneously in the abdomen, thigh, or upper arm.

Saxenda requires daily subcutaneous injections starting at 0.6 mg, with weekly increments of 0.6 mg until the maintenance dose of 3 mg daily is reached [2]. The multi-dose pen contains enough liraglutide for several days, requiring patients to adjust the dose dial daily. This daily commitment demands consistent routine and may present adherence challenges for patients with irregular schedules or needle aversion.

From a practical standpoint, the once-weekly Wegovy injection offers greater convenience and may improve long-term adherence compared to daily Saxenda administration. UK patients in our clinical experience often report that weekly dosing fits more naturally into their lifestyle, reducing the mental burden of daily medication management. However, some patients prefer the flexibility of daily dosing to adjust timing around social events or travel, making Saxenda a viable alternative for specific circumstances.

Side Effects and Tolerability: What to Expect

Both Wegovy and Saxenda share a similar side effect profile due to their common GLP-1 receptor agonist mechanism [1][2]. The most frequently reported adverse effects include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, particularly during the initial dose escalation phase. These gastrointestinal symptoms typically diminish over 4-8 weeks as your body adapts to the medication.

In the STEP trials, 74% of Wegovy patients experienced gastrointestinal adverse events, with nausea being most common at 44% incidence [1]. The SCALE trials reported similar rates with Saxenda, with 39% experiencing nausea and 21% reporting vomiting [2]. Importantly, the gradual dose titration protocols for both medications are specifically designed to minimise these effects, and most patients find symptoms manageable with dietary modifications such as smaller, more frequent meals.

Serious adverse events are uncommon but include potential risks of pancreatitis, gallbladder disease, and thyroid C-cell tumours observed in rodent studies (though not confirmed in humans) [4]. Both medications carry contraindications for patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your UK prescriber will conduct a thorough medical history assessment to identify any contraindications before prescribing either treatment.

Managing Common Side Effects

Our clinical team at Cured Pharmacy provides detailed guidance on managing gastrointestinal symptoms, including avoiding high-fat meals, eating slowly, staying well-hydrated, and timing injections to minimise disruption. Superintendent pharmacist Tarun Kumar (GPhC 2233073) and our UK prescribers offer ongoing support throughout your treatment journey to optimise tolerability and outcomes.

Wegovy vs Saxenda Price UK: Cost Considerations

At Cured Pharmacy, Wegovy starts from £79.00 per pen with transparent upfront pricing displayed before your free online consultation. This competitive pricing includes UK prescriber assessment, genuine UK-licensed medication, and discreet next-day delivery across the UK. We guarantee the lowest prices in the UK market, ensuring you receive clinically proven weight loss treatment without premium markups.

Cost considerations extend beyond per-dose pricing to include treatment duration and total monthly expenditure. With Wegovy's once-weekly dosing, you require four pens per month at maintenance dose, whereas Saxenda's daily injections necessitate approximately one pen per week. When evaluating total treatment costs, factor in both the per-unit price and the dosing frequency to determine your monthly investment.

Both treatments represent a financial commitment to long-term weight management, as clinical trials demonstrate that weight regain commonly occurs upon discontinuation [1][2]. UK patients should view these medications as part of a comprehensive lifestyle programme rather than a short-term solution, with ongoing costs balanced against the significant health benefits of sustained weight reduction, including improved cardiovascular risk markers and glycaemic control.

Which Treatment Is Right for You: Wegovy vs Saxenda UK Comparison

Selecting between Wegovy and Saxenda depends on multiple factors including your weight loss goals, lifestyle preferences, previous medication experience, and medical history. Wegovy may be more suitable if you seek maximum weight reduction based on clinical trial data, prefer once-weekly dosing for convenience, or have struggled with adherence to daily medications in the past.

Saxenda remains an appropriate choice for patients who prefer daily dosing flexibility, have previously responded well to liraglutide, or are starting their first GLP-1 treatment and want the option to adjust timing more frequently. Some patients also find the lower starting dose of Saxenda helpful for assessing initial tolerability before committing to weekly injections.

Your UK prescriber will evaluate your individual circumstances during the online consultation, considering your BMI, weight-related comorbidities, previous weight loss attempts, current medications, and personal preferences. This personalised assessment ensures you receive the most appropriate treatment for your specific needs, with ongoing monitoring to optimise results and manage any side effects that may arise.

Starting Your Weight Loss Journey at Cured Pharmacy

Our streamlined online consultation takes under 3 minutes and connects you with UK-registered prescribers who specialise in weight management. All prescription medications require clinical assessment, and our team will only prescribe treatments that are safe and appropriate for your individual health profile. With discreet packaging, genuine UK-licensed medicines, and ongoing clinical support, Cured Pharmacy provides a comprehensive service designed around your needs.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
3. Shi, Q., et al. (2022). Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. The Lancet, 399(10321), 259–269. https://doi.org/10.1016/S0140-6736(21)01640-8 [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency (MHRA). (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. https://www.gov.uk/guidance/semaglutide-wegovy-2-4-mg-for-weight-management [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to prescribed treatment and lifestyle modifications.